John C. Morris

Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology,
Director of the Charles F. and Joanne Knight Alzheimer’s Disease Research Center.
more about this speaker

Date: October 12, 2015
Time: 12:00 pm – 2:00 pm
Venue: Whittemore House

Abstract: All clinical trials of putative “disease-modifying” anti-Alzheimer therapies have all failed to demonstrate clinical benefit for individuals with symptomatic AD. In response, “secondary prevention” trials of anti-Alzheimer drugs in asymptomatic persons who are at increased risk for developing symptomatic AD are being implemented. Advantages to using a cohort with autosomal dominant AD (ADAD) in these trials are that asymptomatic mutation carriers are destined to develop symptomatic AD and do so at a predictable age. Disadvantages of the ADAD cohorts include the rarity of ADAD individuals (only ~513 families worldwide), their geographical dispersion, and a pathobiology that may differ from that for the far more common “sporadic” late onset AD (LOAD). There are also designs for secondary prevention trials for people at risk for LOAD. About one-third of cognitively normal (CN) older adults have preclinical AD, as identified by elevated cerebral cortical retention of tracers for amyloid-beta (Aβ). However, it is not established that preclinical AD inevitably predicts symptomatic AD. Further characterization of neuronal injury markers in preclinical AD will better inform the timing of interventions for secondary prevention trials.

LUNCH MENU

• Lemon Baked Cod, Tomato, Basil Pesto with Asiago Cheese  & Vegetable Jasmine Rice
• Vegetable Quiche 
• ½ Ham & Cream Cheese Salad Sandwich on Toasted White Bread, Lettuce with Fresh Fruit & Cup of Vegetable Soup
• Whole Ham & Cream Cheese Salad Sandwich on with Fresh Fruit
• Chicken Caesar Salad

      Dessert

Vanilla Ice Cream with a Homemade Cookie